GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt · Delayed Price · Currency is EGP 414.30
+69.05 (20.00%)
At close: Aug 4, 2026
GlaxoSmithKline S.A.E Financials Overview
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 3,731 | 3,731 | 2,991 | 2,240 | 1,823 | 1,812 |
Revenue Growth | 24.73% | 24.73% | 33.51% | 22.87% | 0.62% | -9.07% |
Gross Profit Gross Profit Growth | 679.77 | 679.77 | 933.94 | 789.12 | 557.4 | 706.66 |
Operating Income Operating Income Growth | 216.65 | 216.65 | 425.87 | 448.83 | 15.33 | 242.16 |
Net Income Net Income Growth | 213.23 | 213.23 | 173.98 | 60.46 | 735.38 | 154.64 |
Earnings Per Share EPS Growth | 2.55 | 2.55 | 2.08 | 0.72 | 8.81 | 1.85 |
EPS Growth | 22.56% | 22.56% | 187.78% | -91.78% | 375.56% | 449.70% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 479.69 | 479.69 | 75.47 | 829.34 | 585.85 | 73.57 |
Total Debt Total Debt Growth | 81.76 | 81.76 | 119.48 | 97.03 | 69.55 | 179.97 |
Net Cash (Debt) Net Cash Growth | 397.93 | 397.93 | -44.01 | 732.32 | 516.3 | -106.41 |
Net Cash Growth | - | - | - | 41.84% | - | - |
Net Cash Per Share Net Cash Per Share Growth | 4.76 | 4.76 | -0.53 | 8.77 | 6.18 | -1.27 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 240.83 | 240.83 | -404.15 | 302.27 | 1,036 | 192.19 |
Capital Expenditures CapEx Growth | -177.28 | -177.28 | -124.34 | -77.08 | -48.76 | -35.76 |
Free Cash Flow Free Cash Flow Growth | 63.55 | 63.55 | -528.49 | 225.2 | 987.26 | 156.43 |
Free Cash Flow Growth | - | - | - | -77.19% | 531.14% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 18.22% | 18.22% | 31.23% | 35.23% | 30.57% | 39.00% |
Operating Margin | 5.81% | 5.81% | 14.24% | 20.04% | 0.84% | 13.36% |
Pretax Margin | 8.72% | 8.72% | 11.33% | 5.34% | -3.45% | 9.90% |
Profit Margin | 5.72% | 5.72% | 5.82% | 2.70% | 40.33% | 8.53% |
FCF Margin | 1.70% | 1.70% | -17.67% | 10.05% | 54.15% | 8.63% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 1.000 | 1.000 | - | 0.750 | - | 0.750 |
Dividend Per Share Growth | 0% | - | - | - | - | - |
Dividend Yield | 0.24% | 1.60% | - | 2.20% | - | 2.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 129.82 | 24.93 | 17.28 | 49.11 | 4.33 | 16.68 |
P/FCF Ratio | 435.55 | 83.64 | - | 13.18 | 3.23 | 16.49 |
PS Ratio | 7.42 | 1.43 | 1.00 | 1.33 | 1.75 | 1.42 |